The United Kingdom and the United States have established a significant bilateral deal that will preserve zero tariffs on British pharmaceutical products entering the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has pledged to boost funding on medicines through the public health system. This pledge ensures that import taxes on these key products will be held at zero for a timeframe of 36 months.
This deal is in response to previous threats to dramatically increase duties on patented drug imports, with potential rates mentioned as high as 100%.
"This arrangement with the United Kingdom strengthens the worldwide climate for new treatments and establishes much-needed balance to U.S.–U.K. pharmaceutical trade," an announcement noted.
Trade Impact
Medicines constitute one of the the United Kingdom's most significant export categories to the America, which is easily the biggest buyer for major UK drugmakers.
Export figures show that in the one-year period to the end of September, the UK shipped drugs valued at billions to the US. This value accounted for a significant portion of British export trade in that span.
"This guarantee secures jobs, increases capital expenditure and sets the stage for the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary stated.
Key UK Commitments
The agreement entails several notable changes from the British government:
- Price Threshold Increase: The UK will lift the price threshold at which it judges new medicines to be too expensive by a quarter.
- Increased NHS Spending: There is a target to increase overall NHS spending on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must return to the NHS to control costs will be capped at 15%. Last year, rebates exceeded twenty percent.
Broader Context
The pact comes amid a long-running dispute between the sector and the ministers over drug pricing and NHS adoption.
These tensions were intensified by arguments that US customers were paying a premium for the equivalent treatments than people in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been delayed or scrapped, while major funding commitments have been announced toward American operations.
The Science Minister publicly accepted that the NHS had to increase expenditure on treatments, noting that its spending on drugs had declined as a share of its resources over the last ten years.
